Serina Therapeutics (SER) Fundamental Analysis: Revenue, Earnings & Valuation

8.94 / 10

Outperform

Fundamental analysis rates SER as Outperform with an 8.9/10 score. Key strengths include PB‑ROE, Profit‑MV, Cash‑UP and cash‑MV, while current‑asset turnover and inventory turnover days lag. Weighted fund‑flow score is 8.94, indicating robust underlying value.

Analysis Checks(7/10)

Profit-MV

Value0.41

Score2/3

Weight3.34%

1M Return0.17%

Net income-Revenue

Value-0.16

Score2/3

Weight-4.29%

1M Return-0.22%

PB-ROE

Value3.18

Score2/3

Weight30.22%

1M Return1.39%

Current assets turnover ratio

Value0.02

Score1/3

Weight-5.39%

1M Return-0.27%

Cash-UP

Value-0.01

Score3/3

Weight60.49%

1M Return2.87%

Total assets turnover ratio

Value0.01

Score2/3

Weight28.96%

1M Return1.43%

Cost of sales ratio (%)

Value70.30

Score3/3

Weight36.86%

1M Return1.95%

Asset-MV

Value-0.48

Score1/3

Weight-17.52%

1M Return-0.83%

Inventory turnover days

Value230.09

Score1/3

Weight-47.06%

1M Return-2.65%

Cash-MV

Value-0.09

Score2/3

Weight14.40%

1M Return0.79%

Is SER undervalued or overvalued?

SER scores 8.94/10 on fundamentals and holds a Discounted valuation at present. Backed by its -1507.71% ROE, -16061.21% net margin, -1.76 P/E ratio, 20.54 P/B ratio, and -128.05% earnings growth, these metrics solidify its Outperform investment rating.